Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Halofuginone hydrobromide may stop the growth of solid tumors by stopping blood
flow to the tumor.
PURPOSE: Phase I trial to study the effectiveness of halofuginone hydrobromide in treating
patients who have progressive advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC